New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma

Melanoma Research

Volumn 27, Issue 2, 2017, Pages 155-158

  Behling, Juliane ^a   Kaes, Joachim ^a   Münzel, Thomas ^a   Grabbe, Stephan ^a   Loquai, Carmen ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

anti programmed cell death 1; autoimmune myositis; malignant melanoma; myocarditis; third degree atrioventricular block

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; HEPARIN; IPILIMUMAB; MYOGLOBIN; NIVOLUMAB; NORADRENALIN; SIMVASTATIN; SULTAMICILLIN; TROPONIN I; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE INDUCED MYOSITIS; BRADYCARDIA; CANCER IMMUNOTHERAPY; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPLETE HEART BLOCK; CREATINE KINASE BLOOD LEVEL; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; GENE MUTATION; HUMAN; INTUBATION; LIVER METASTASIS; LUNG INFILTRATE; MALE; MEDICAL CARE; METASTATIC UVEA MELANOMA; MIDDLE AGED; MYALGIA; MYOSITIS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; RESPIRATORY FAILURE; SYSTEMIC THERAPY; THORAX RADIOGRAPHY; TRANSLUMINAL CORONARY ANGIOPLASTY; ATRIOVENTRICULAR BLOCK; CHEMICALLY INDUCED; COMPLICATION; FATALITY; MELANOMA; PATHOLOGY; SECONDARY; UVEA TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ATRIOVENTRICULAR BLOCK; AUTOIMMUNE DISEASES; FATAL OUTCOME; HUMANS; MALE; MELANOMA; MIDDLE AGED; MYOSITIS; UVEAL NEOPLASMS;

EID: 85006324675     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000314     Document Type: Article

References (18)

1. U.S. Food and Drug Administarion. FDA approves Keytudra for advanced melanoma; 2014. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm. [Accessed 25 November 2016].
2. Wolchok JD. PD-1 blockers. Cell 2015; 162:937.
3. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015; 76-83.
4. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26:2375-2391.
5. Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Uqurel S, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60:190-209.
6. Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A, et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015; 3:11.
7. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-133.
8. Eggermont AM, Maio M, Robert C. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. Semin Oncol 2015; 42:429-435.
9. Mehta A, Gupta A, Hannallah F, Koshy T, Reimold S. Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma. Melanoma Res 2016; 26:319-320.
10. Guglin M, Nallamshetty L. Myocarditis: diagnosis and treatment. Curr Treat Options Cardiovasc Med 2012; 14:637-651.
11. Jastrzebski M, Hart R, Czarnecka D. Wide QRS complex tachycardia in a patient with complete heart block: what is the mechanism? J Cardiovasc Electrophysiol 2015; 27:765-767.
12. Rösler KM, Scheidegger O. Myositides: what is the current situation? Z Rheumatol 2015; 74:496-506.
13. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28:1-39.e14.
14. Kou S, Caballero L, Dulgheru R, Voilliot D, de Sousa C, Kacharava G, et al. Echocardiographic reference ranges for normal cardiac chamber size: results from the NORRE study. Eur Heart J Cardiovasc Imaging 2015; 15:680-690.
15. Felker GM, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Baughman KL, et al. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol 2000; 36:227-232.
16. Bami K, Haddad T, Dick A, Dennie C, Dwivedi G. Noninvasive imaging in acute myocarditis. Curr Opin Cardiol 2016; 31:217-223.
17. Khan S, Christopher-Stine L. Polymyositis, dermatomyositis, and autoimmune necrotizing myopathy: clinical features. Rheum Dis Clin North Am 2011; 37:143-158.
18. Ascierto PA, Marincola FM, Atkins MB. What's new in melanoma? Combination!. J Transl Med 2015; 13:213.